Key result
MeRes100 bioresorbable scaffold yields a ~1% 1-year major cardiovascular events rate with zero scaffold thrombosis.
Answers are grounded in this paper and cite their sources.
Prospective multicentre trial demonstrates safety of a bioresorbable scaffold in coronary artery lesions, indicating potential for broader clinical use.
AIMS: The MeRes-1 trial sought to study the safety and effectiveness of a novel sirolimus-eluting bioresorbable vascular scaffold (MeRes100 BRS) in treating de novo native coronary artery lesions by clinical evaluation and using multiple imaging modalities. METHODS AND RESULTS: The MeRes-1 first-in-human trial was a single-arm, prospective, multicentre study, which enrolled 108 patients with de novo coronary artery lesions (116 scaffolds were deployed to treat 116 lesions in 108 patients). At six months, quantitative coronary angiography revealed in-scaffold late lumen loss of 0.15±0.23 mm with 0% binary restenosis. Optical coherence tomography demonstrated minimum scaffold area (6.86±1.73 mm2) and percentage neointimal strut coverage (99.30%). Quantitative intravascular ultrasound analysis confirmed a 0.14±0.16 mm2 neointimal hyperplasia area. At one year, major adverse cardiac events, a composite of cardiac death, any myocardial infarction and ischaemia-driven target lesion revascularisation, occurred in only one patient (0.93%) and there was no scaffold thrombosis reported. At one year, computed tomography angiography demonstrated that all scaffolds were patent and in-scaffold mean percentage area stenosis was 11.33±26.57%. CONCLUSIONS: The MeRes-1 trial demonstrated the safety and effectiveness of MeRes100 BRS. The favourable clinical outcomes and effective vascular responses have provided the basis for further studies in a larger patient population. The MeRes-1 trial is registered at the Clinical Trials Registry-India.
No takes yet. Share an insight, caveat, or question.
Seth et al. (2017) studied De novo native coronary artery lesions (n=108). MeRes100 sirolimus-eluting bioresorbable vascular scaffold (BRS) was evaluated on Major adverse cardiac events (composite of cardiac death, any myocardial infarction, and ischaemia-driven target lesion revascularisation) at 1 year. The MeRes100 sirolimus-eluting bioresorbable scaffold yielded 0.93% major adverse cardiac events and 0% scaffold thrombosis at 1 year, with 0.15±0.23 mm late lumen loss at 6 months.
Synapse has enriched 10 related papers. Consider them for comparative context: